Page last updated: 2024-11-11

ro 42-5892

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

remikiren : An L-histidine derivative that is L-histidine in which one of the amino hydrogens is replaced by a (2S)-2-[(2-methylpropane-2-sulfonyl)methyl]-3-phenylpropanoyl group and the carboxy group is replaced by a [(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino group. It is a renin inhibitor which was under development for the treatment of hypertension (now discontinued). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6324659
CHEMBL ID31601
CHEBI ID8803
SCHEMBL ID156393
SCHEMBL ID19792404
MeSH IDM0180289

Synonyms (44)

Synonym
2-benzyl-n-[1-(1-cyclohexylmethyl-3-cyclopropyl-2,3-dihydroxy-propylcarbamoyl)-2-(1h-imidazol-4-yl)-ethyl]-3-(2-methyl-propane-2-sulfonyl)-propionamide(remikiren)
(s)-2-benzyl-n-[(s)-1-((1s,2r,3s)-1-cyclohexylmethyl-3-cyclopropyl-2,3-dihydroxy-propylcarbamoyl)-2-(1h-imidazol-4-yl)-ethyl]-3-(2-methyl-propane-2-sulfonyl)-propionamide
bdbm50077669
nalpha-[(2s)-2-benzyl-3-(tert-butylsulfonyl)propanoyl]-n-[(1s,2r,3s)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-l-histidinamide
remikiren [inn]
1h-imidazole-4-propanamide, n-(1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-alpha-((2-(((1,1-dimethylethyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (1s-(1r*(r*(r*)),2s*,3r*))-
(alphas)-alpha-((alphas)-alpha-((tert-butylsulfonyl)methyl)hydrocinnamamido)-n-((1s,2r,3s)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide
ccris 6519
remikiren
C07465
ro 42-5892
126222-34-2
DB00212
ro-42-5892
REM ,
CHEMBL31601 ,
D09038
remikiren (inn)
(2s)-2-benzyl-3-tert-butylsulfonyl-n-[(2s)-1-[[(2s,3r,4s)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]propanamide
unii-lc7fbl96a4
lc7fbl96a4 ,
3D91
1h-imidazole-5-propanamide, n-[(1s,2r,3s)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-alpha-[[(2s)-2-[[(1,1-dimethylethyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-, (alphas)-
remikiren [usan]
remikiren [mart.]
remikiren [who-dd]
(alphas)-n-[(1s,2r,3s)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-alpha-[[(2s)-2-[[(1,1-dimethylethyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-1h-imidazole-5-propanamide
UXIGZRQVLGFTOU-VQXQMPIVSA-N
(s)-alpha-[(s)-alpha-[(tert-butylsulphonyl)methyl]hydrocinnamamido]-n-[(1s,2r,3s)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]imidazole-4-propionamide
(s)-alpha-[(s)-alpha-[(tert-butylsulphonyl)methyl]hydrocinnamamido]-n-[(1s,2r,3s)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-imidazole-4-propionamide
SCHEMBL156393
n-[(2s,3r,4s)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-nalpha-{(2s)-2-[(2-methylpropane-2-sulfonyl)methyl]-3-phenylpropanoyl}-l-histidinamide
remikireno
CHEBI:8803
nalpha-[(2s)-2-benzyl-3-(tert-butylsulfonyl)propanoyl]-n-[(2s,3r,4s)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-l-histidinamide
remikirene
remikirenum
DTXSID60155121
135669-48-6
Q417432
SCHEMBL19792404
CS-0017528
HY-A0184
AKOS040753724

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Several statistical regression models and artificial neural networks were used to predict the hepatic drug clearance in humans from in vitro (hepatocyte) and in vivo pharmacokinetic data and to identify the most predictive models for this purpose."( Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
Coassolo, P; Lavé, T; Schneider, G, 1999
)
0.3
" Pharmacokinetic parameters were estimated using model independent techniques and the concentration-effect relationship was evaluated using population pharmacometric methods."( Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients.
Birnböck, H; Kleinbloesem, CH; Kobrin, I; Leube, J; Van Brummelen, P; Weber, C, 1993
)
0.5
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33

Bioavailability

ExcerptReferenceRelevance
" New generation renin inhibitors with higher potency and greater oral bioavailability may join the antihypertensive armamentarium."( Renin inhibitors in hypertension.
Boger, RS; Glassman, HN; Luther, RR, 1991
)
0.28
" Intravenous drug administration did not further reduce blood pressure, suggesting that the mode of action and not the low bioavailability was the limiting factor for the low efficacy."( Efficacy and tolerability of the renin inhibitor Ro 42-5892 in patients with hypertension.
Buchmann, MS; Fahrner, E; Haug, G; Kleinbloesem, CH; Lenders, JW; Pozenel, H; Rongen, GA; Weber, C; Welker, H; Woittiez, AJ, 1993
)
0.54
" Systemic plasma clearance, volume of distribution, and absolute bioavailability of remikiren were in the magnitude of 900 ml/min, 70 L, and below 1%, respectively."( Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects.
Belz, GG; Dellenbach, M; Fahrner, E; Kleinbloesem, CH; Schröter, V; Weber, C; Welker, H, 1993
)
0.29
" Consistent with the high hepatic clearance, oral bioavailability was low ( < or = 6%) in each species."( Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates.
Chou, RC; Clozel, JP; Coassolo, P; Fischli, W, 1996
)
0.29
" Therefore, various direct renin inhibitors (DRIs) have been researched over recent decades; however, most exhibited poor pharmacokinetics and oral bioavailability due to the peptidomimetic or nonpeptidomimetic structures with a molecular weight (MW) of >600, and only aliskiren is approved."( Discovery of Novel 2-Carbamoyl Morpholine Derivatives as Highly Potent and Orally Active Direct Renin Inhibitors.
Akatsuka, H; Awai, N; Iijima, D; Iijima, T; Inui, Y; Kashima, A; Kawaguchi, T; Ke, Y; Nishio, M; Shen, J; Sugama, H; Takahashi, Y; Takebe, T; Takedomi, K; Togashi, Y; Xia, G; Xie, J; Yoneda, H, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" A prolonged hypotensive effect is seen following single doses of enalkiren and RO 42-5892, and repeated dosing with enalkiren results in sustained hypotensive effect without tachyphylaxis."( Renin inhibitors in hypertension.
Boger, RS; Glassman, HN; Luther, RR, 1991
)
0.51
"With both intravenous and oral doses renin activity fell in 10 minutes to undetectably low values, while angiotensin II concentration fell overall by 80-90% with intravenous dosing and by 30-40% after the oral dose."( Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.
Admiraal, PJ; Derkx, FH; Man in 't Veld, AJ; Mulder, P; Ritsema van Eck, HJ; Schalekamp, MA; van Brummelen, P; van den Meiracker, AH, 1990
)
0.51
") dosing in humans."( Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans.
Birnbock, H; Doig, JK; Jones, CR; MacFadyen, RJ; Reid, JL, 1995
)
0.54
" 'Simultaneous' collection of blood samples from the hepatic portal vein and aorta of rat confirmed that shortly after oral dosing the intact drug did cross the liver; however, the later collections contained predominantly more polar metabolites."( Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates.
Chou, RC; Clozel, JP; Coassolo, P; Fischli, W, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
vasodilator agentA drug used to cause dilation of the blood vessels.
peptidomimeticA small protein-like chain designed to mimic a peptide.
EC 3.4.23.15 (renin) inhibitorAn EC 3.4.23.* (aspartic endopeptidase) inhibitor that interferes with the activity of renin (EC 3.4.23.15).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
sulfoneAn organosulfur compound having the structure RS(=O)2R (R =/= H).
diolA compound that contains two hydroxy groups, generally assumed to be, but not necessarily, alcoholic. Aliphatic diols are also called glycols.
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
cyclopropanesCyclopropane and its derivatives formed by substitution.
L-histidine derivativeA proteinogenic amino acid derivative resulting from the formal reaction of L-histidine at the amino group, carboxy group, or the imidazolyl moiety, or from the replacement of any hydrogen of L-histidine by a heteroatom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ReninHomo sapiens (human)IC50 (µMol)0.00000.00000.77968.2000AID198513
ReninHomo sapiens (human)Ki0.00070.00001.80787.4000AID39381
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ReninHomo sapiens (human)Kd0.00010.00010.00410.0080AID1525520
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
kidney developmentReninHomo sapiens (human)
mesonephros developmentReninHomo sapiens (human)
angiotensin maturationReninHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionReninHomo sapiens (human)
proteolysisReninHomo sapiens (human)
regulation of blood pressureReninHomo sapiens (human)
male gonad developmentReninHomo sapiens (human)
hormone-mediated signaling pathwayReninHomo sapiens (human)
response to lipopolysaccharideReninHomo sapiens (human)
response to immobilization stressReninHomo sapiens (human)
drinking behaviorReninHomo sapiens (human)
regulation of MAPK cascadeReninHomo sapiens (human)
cell maturationReninHomo sapiens (human)
amyloid-beta metabolic processReninHomo sapiens (human)
response to cAMPReninHomo sapiens (human)
response to cGMPReninHomo sapiens (human)
cellular response to xenobiotic stimulusReninHomo sapiens (human)
juxtaglomerular apparatus developmentReninHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
aspartic-type endopeptidase activityReninHomo sapiens (human)
signaling receptor bindingReninHomo sapiens (human)
insulin-like growth factor receptor bindingReninHomo sapiens (human)
protein bindingReninHomo sapiens (human)
peptidase activityReninHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
extracellular regionReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membraneReninHomo sapiens (human)
apical part of cellReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID540230Dose normalised AUC in rat after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID21853In vivo clearance in dog1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID198513In vitro inhibitory activity against purified recombinant human renin1999Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10
Substituted piperidines--highly potent renin inhibitors due to induced fit adaptation of the active site.
AID540232Dose normalised AUC in monkey after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID21850In vitro clearance in dog in 1000000 cells; not available1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID12234881-Octanol-water distribution coefficient, log D of the compound at pH 7.42012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID39381Binding affinity against aspartic protease renin.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID20787Oral bioavailability in human2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID21858In vivo clearance in rat1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID21851In vitro clearance in human in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID540233Dose normalised AUC in human after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1893648Oral bioavailability in human2022ACS medicinal chemistry letters, Aug-11, Volume: 13, Issue:8
Discovery of Novel 2-Carbamoyl Morpholine Derivatives as Highly Potent and Orally Active Direct Renin Inhibitors.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1525520Binding affinity to renin (unknown origin)2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Why Some Targets Benefit from beyond Rule of Five Drugs.
AID21856In vivo clearance in human1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID540231Dose normalised AUC in dog after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID21852In vitro clearance in rat in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (68)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's49 (72.06)18.2507
2000's11 (16.18)29.6817
2010's6 (8.82)24.3611
2020's2 (2.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.92 (24.57)
Research Supply Index4.49 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials19 (27.54%)5.53%
Reviews9 (13.04%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (59.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]